Related Image: Mayo Clinic's Dr. Denis Cortese Receives NCHL'S 2009 National Healthcare Leadership Award |
(Date:11/25/2009)... have found evidence of a statistically significan...atients whose estrogen receptor (ER)-positive tumo... at serine-118 (ER-alpha S118-P), according to a b... the Journal of the National Cancer Institute . ,...stant to tamoxifen. Preclinical studies have shown...
(Date:11/25/2009)...low-up period was too short to draw definite concl.... 25 (HealthDay News) -- In diabetic patients with... difference in outcomes at one year whether patien...ting, British researchers report. , Bypass surg...atients with coronary artery disease. However, les...
(Date:11/25/2009)...etfulness could lead mothers to overlook needed ca...HealthDay News) -- A mother,s depression can worse... , Their six-month study of 262 black mothers a...s had more depressive symptoms had more frequent a...er depressive symptoms had less frequent asthma sy...
(Date:11/25/2009)...RK,Nov.25/PRNewswire/-- MISSIONSkincare ®ispr...rSt.Jude.AspartofGNC,sannualSt.Jude ThanksandGivin...incare,s new SUPER-C(TM)LipBalm willbedonatedtoS...tomakea$1,$5or$10donationatcheckoutatoneoftheir5,0...han$1millionforSt.Judeduringtheir2009 ThanksandGiv...
(Date:11/25/2009)...Mass. -- A cancer vaccine carried into the body on...is the first to successfully eliminate tumors in m... Science Translational Medicine . , The new app... at Harvard University, uses plastic disks impregn...der the skin to reprogram the mammalian immune sys...
Breaking Medicine News(10 mins):Health News:Stenting May Equal Bypass for Diabetic Heart Patients 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 3Health News:Mom's Depression May Worsen Child's Asthma 2Health News:MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R) 2Health News:Implant-based cancer vaccine is first to eliminate tumors in mice 2...ing poorly one year later, study found , ,...attack is apparently not sufficient reason for mos...study finds. , "We found that diet quality is poor...al School, in Worcester. , But he warned that pati...
...s in young womens drinking during the transition f...can have dangerous physical, sexual and psychologi... University at Buffalos Research Institute on Addi...incoming freshmen women who participated in the st...
...Red Cross for Disaster Relief; Opens Free ... BRENTWOOD, Tenn., Feb. 8 Responding to the,deva...e earlier this week,UnitedHealthcare of the River ...ll Tennesseans who may be coping with the,emotiona...
...t sand boosts gastrointestinal illness risk, study...-- When you,re at the beach, you may want to stay ...sity of Florida researcher who conducted a two-yea...exposure to sand on the upper beach," Tonya D. Bon...
...e if its kind in the Pacific Northwest, SEATTLE, ...d Northwest Hospital & Medical Center today announ...he development of a new, state-of-the-art,cancer t...2006 and has since been working to secure financin...
...cot Financial, a leading,provider of convenient, c...o come out and have fun "the Amscot way" at its op...m. at 3260 Vineland Road in Kissimmee. Amscot,will... the disease., (Logo: http://www.newscom.com/cgi...
Other Medicine News:Health News:Heart Attack Seldom Leads to Healthier Diet 2Health News:Heart Attack Seldom Leads to Healthier Diet 3Health News:A dangerous transition: High school to the first year of college 2Health News:A dangerous transition: High school to the first year of college 3Health News:A dangerous transition: High school to the first year of college 4Health News:UnitedHealthcare of the River Valley Acts to Help Tennessee Victims of Storm Devastation 2Health News:UnitedHealthcare of the River Valley Acts to Help Tennessee Victims of Storm Devastation 3Health News:Staying Dry at Beach May Spare Your Stomach 2Health News:Seattle Cancer Care Alliance and Northwest Hospital Sign Letter of Intent to Develop Proton Therapy Center for Cancer Treatment 2Health News:Seattle Cancer Care Alliance and Northwest Hospital Sign Letter of Intent to Develop Proton Therapy Center for Cancer Treatment 3Health News:Amscot Financial Contributes to the Juvenile Diabetes Research Foundation, Supporting Upcoming 'Walk for a Cure' 2(Date:11/25/2009)....25/PRNewswire/--SwissrayInternational,Inc.aleadin...ems,announcedtodaythatitsoperationshavebeenacquire...owingSwissray,smedicalimagingbrand.Theacquisitioni...ntractsandinventory.After25yearsofsuccessandgrowth...icaladvancementswithstableandsteadygrowth. ,, "...
(Date:11/25/2009)...ire/--Reportlinker.comannouncesthatanewmarketresea...nagement-GlobalTrends ,, http://www.reportli...html ,, Widespreadavailabilityofgenericdrugs,e...rugshaveacceleratedthepaceofgrowthinthepainmanagem...recontinuetoshapedemandforservices,drugsanddevices...
(Date:11/25/2009)...v.25/PRNewswire/-- ChemoCentryx,Inc.,announcedtod...CT-1(theProspectiveRandomizedOralTherapyEvaluation...npatientswithmoderate-to-severeCrohn,sdiseasedemon...rabilityprofile.Thestudydemonstratedevidenceofclin...edasa70-pointdecreaseintheCrohn,sDiseaseActivityIn...
Breaking Medicine Technology:Swissray International Announces New Ownership 2Reportlinker Adds Pain Management - Global Trends 2Reportlinker Adds Pain Management - Global Trends 3Reportlinker Adds Pain Management - Global Trends 4Reportlinker Adds Pain Management - Global Trends 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5SXC Health Solutions announces pricing of upsized public offering of common shares 57606 1SXC Health Solutions announces pricing of upsized public offering of common shares 57606 2SXC Health Solutions announces pricing of upsized public offering of common shares 57606 3SXC Health Solutions announces pricing of upsized public offering of common shares 57606 4SXC Health Solutions announces pricing of upsized public offering of common shares 57606 5AstraZeneca Accepts Secretary of Defense Award for Supporting Employees Serving in National Guard and Reserve 57603 1AstraZeneca Accepts Secretary of Defense Award for Supporting Employees Serving in National Guard and Reserve 57603 2Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptam 14136 1Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptam 14136 2Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptam 14136 3...--Apr 17, 2007 - A 9-month, randomized,double-bli...omparing a 40 mg dose of COPAXONE(R) given daily t...owed a 38 percent greater,reduction in inflammator...ce images (MRI) of the brain. In addition, patient...ean on-trial relapse rate,of 77 percent when compa...
...erican Association for Cancer Research,annual meet...-FirstCall/ --,Medarex, Inc. today presented precl...ity from two separate studies exploring the,effica...ti-CD70,antibody-drug conjugates. CD19 and CD70 ar...jugate approach to cancer therapy. They are,expres...
Other Medicine Technology:Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 2Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 3Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 4Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 5Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 2Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 3Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 4MP20
... IntelliVue MP90 is designed to match the pace and...nts. Built on Philips strong heritage in patient m...nt displays has highly flexible screen configurati...-in clinical support tools such as Event Surveilla...
...xNet adds wireless capability to Welch Allyn's com... the Flexible Monitoring concept to provide vital ...o anywhere. FlexNet links multiple devices such as...reless bedside monitors to Acuity® Central Mon...
Spot Vital Signs
Medicine Products: